Terms: = Ovarian cancer AND MYH9, P35579, 4627, ENSG00000100345, DFNA17 AND Prognosis
4 results:
1. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to myh9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
2. MYH10 Combines with myh9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous ovarian cancer Carcinogenesis, Progression, and Cisplatin Resistance.
Liu L; Chen C; Liu P; Li J; Pang Z; Zhu J; Lin Z; Zhou H; Xie Y; Lan T; Chen ZS; Zeng Z; Fang W
Adv Sci (Weinh); 2023 May; 10(14):e2203423. PubMed ID: 36929633
[TBL] [Abstract] [Full Text] [Related]
3. miR-6089/myh9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
[TBL] [Abstract] [Full Text] [Related]
4. Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis.
Birner P; Schindl M; Obermair A; Plank C; Breitenecker G; Kowalski H; Oberhuber G
Anticancer Res; 2000; 20(5A):2981-5. PubMed ID: 11062711
[TBL] [Abstract] [Full Text] [Related]
